MedTrace Logo

Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection

NCT03853369 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2019-03-14

No results posted yet for this study

Summary

Retrospective and Prospective single arm, observational study to evaluate efficacy and safety of NIF in the treatment of ventricular tachycardia and ventricular fibrillation. The information registration of the target population will be collected with the hospital HIS system or LIS system.

Conditions

  • Ventricular Tachycardia
  • Ventricular Fibrillation

Interventions

DRUG

Nifekalant hydrochloride

Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Sichuan Baili Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yong Huo · Peking University First Hospital

  • Jing Zhou · Peking University First Hospital

  • Min Yi Cui · Peking University First Hospital

  • Xin Hu · Beijing Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-18
Primary Completion
2019-12-30
Completion
2019-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03853369 on ClinicalTrials.gov